Gan and Lee Pharmaceuticals (SHSE:603087) Other Current Payables: ¥421 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603087 Gan and Lee Pharmaceuticals SHSE:603087
90 GF Score
Price ¥66.34
GF Value ¥73.00
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gan and Lee Pharmaceuticals Other Current Payables?

Gan and Lee Pharmaceuticals SHSE:603087 -2.27% 90 Other Current Payables is ¥421 Mil as of Jun. 2026. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review.

Gan and Lee Pharmaceuticals's Other Current Payables for the quarter that ended in Jun. 2026 was ¥421 Mil.

Gan and Lee Pharmaceuticals's quarterly Other Current Payables declined from Dec. 2025 (¥548 Mil) to Mar. 2026 (¥430 Mil) and declined from Mar. 2026 (¥430 Mil) to Jun. 2026 (¥421 Mil).

Gan and Lee Pharmaceuticals's annual Other Current Payables declined from Dec. 2023 (¥594 Mil) to Dec. 2024 (¥577 Mil) and declined from Dec. 2024 (¥577 Mil) to Dec. 2025 (¥548 Mil).

Gan and Lee Pharmaceuticals Other Current Payables Related Terms

Gan and Lee Pharmaceuticals Other Current Payables Historical Data

* Premium members only.

The historical data trend for Gan and Lee Pharmaceuticals's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan and Lee Pharmaceuticals Other Current Payables Chart

Gan and Lee Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 273.47 676.70 593.77 577.27 547.59

Gan and Lee Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 542.27 489.48 547.59 429.72 421.37
SHSE:603087
90GF Score
Gan and Lee Pharmaceuticals SHSE:603087
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gan and Lee Pharmaceuticals Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of ¥421 Mil mean?
Gan and Lee Pharmaceuticals (SHSE:603087) has a Other Current Payables of ¥421 Mil as of Jun. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Gan and Lee Pharmaceuticals and its competitors.
Is Gan and Lee Pharmaceuticals' Other Current Payables too high?
Gan and Lee Pharmaceuticals' current Other Current Payables is ¥421 Mil. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Other Current Payables compare to ISRG and BDX?
Gan and Lee Pharmaceuticals' Other Current Payables of ¥421 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Medical Devices & Instruments company?
A good Other Current Payables depends on the Medical Devices & Instruments industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Gan and Lee Pharmaceuticals and its competitors. Gan and Lee Pharmaceuticals's current Other Current Payables is ¥421 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Other Current Payables is ¥421 Mil. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Other Current Payables is ¥421 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?

Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued. The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00. GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.

Key valuation signals for SHSE:603087:

  • Other Current Payables: ¥421 Mil
  • GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gan and Lee Pharmaceuticals Business Description

Address No. 8, Nanfengxi 1st Road, Xianxian Town, Tongzhou District, Beijing, CHN, 101109
Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections.
90GF Score

Get the complete analysis for SHSE:603087

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥66.34
Price
¥73.00
GF Value